
British woman dies from rabies - as family speak out to 'prevent this happening to others'
A British grandmother has died after contracting rabies from a "slight scratch" from a puppy during a holiday in Morocco, her family has said.
Yvonne Ford's daughter said she travelled to the North African country in February but did not become ill until two weeks ago.
Robyn Thomson said in a Facebook post: "Our family is still processing this unimaginable loss, but we are choosing to speak up in the hope of preventing this from happening to others.
"She was scratched very slightly by a puppy in Morocco in February. At the time, she did not think any harm would come of it and didn't think much of it.
"Two weeks ago she became ill, starting with a headache and resulted in her losing her ability to walk, talk, sleep, swallow. Resulting in her passing."
Ms Ford, from Barnsley, South Yorkshire, was diagnosed with the virus at Barnsley Hospital.
The UK Health Security Agency (UKHSA) said health workers and close contacts were being assessed and offered vaccination when necessary.
It said there was no risk to the wider public because there is no evidence rabies can be transmitted between people.
What is rabies and how is it treated?
Rabies is caused by a virus invading the central nervous system.
It is spread by mammals - such as cats, dogs, bats, raccoons and foxes - but in the UK it's only found in some bats, according to the NHS.
Once symptoms appear, it is almost always fatal, according to the World Health Organisation (WHO).
The first symptoms can mirror a flu, while later symptoms include numbness or tingling in the affected area, hallucinations, anxiety, difficulty swallowing or breathing, nausea, vomiting, agitation, excessive saliva and paralysis.
But if seen to promptly after a bite, scratch or lick by an animal that may carry the virus, treatment is usually very effective at preventing the condition.
Treatment usually involves two or more doses of the rabies vaccine or a medicine called rabies immunoglobulin, which is a liquid administered to the wound and is only required if the patient has not had the rabies vaccine or has a weakened immune system.
The rabies vaccine is recommended if you're travelling to a part of the world where rabies is more common.
Around 60,000 people die every year from rabies worldwide, with the majority in Africa and Asia, according to the WHO.
Dr Katherine Russell at the UKHSA said: "I would like to extend my condolences to this individual's family at this time.
"If you are bitten, scratched or licked by an animal in a country where rabies is found then you should wash the wound or site of exposure with plenty of soap and water and seek medical advice without delay in order to get post-exposure treatment to prevent rabies."
The UKHSA urges travellers to rabies-affected countries, for example in Asia and Africa, to avoid contact with dogs, cats and other animals wherever possible and check whether a vaccination is needed before travelling.
There have been six cases of human rabies associated with animal exposure abroad that have been reported in the UK between 2000 and 2024.
This includes a case in 2012, when a UK resident died after being bitten by a dog - the most common source of infection in most parts of the world - in South Asia.
The latest case was in 2018, when another Briton died after being bitten by a cat in Morocco.
Latest World Health Organisation figures show a number of deaths from rabies in Morocco have been reported every year from 2010 to 2022.
Rabies does not circulate in either wild or domestic animals in the UK, although some species of bats can carry a rabies-like virus. No human cases of rabies acquired in the UK from animals other than bats have been reported since 1902.

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


BBC News
an hour ago
- BBC News
Southampton lung expert warns indoor air pollution is being overlooked
A leading respiratory expert has warned the dangers of indoor air pollution are being respiratory physician Dr Thom Daniels, from University Hospital Southampton (UHS), says the "invisible threat" may pose an even bigger risk to health than outdoor can trigger short-term respiratory symptoms and make existing conditions such as asthma warning comes as the Royal College of Physicians (RCP) publishes a new report linking air pollution to 30,000 deaths a year in the UK. "We know so much more about outdoor air pollution because it's so much easier to study," says Dr Daniels. "One monitor allows you to know about the air quality for thousands of people. But every single house is different and we spend 90% of our time indoors and until we understand better about indoor air quality, we'll be missing the majority of our air exposure." Particulates and harmful gases come from daily activities within the home such as cooking or using wood burning and other household cleaning products can also add to the problem. People with chronic lung conditions are advised to limit their use where possible."Burning your cooking on your hob really produces a lot of the very small material, particulate matter," continues Dr Daniels."Dust is unavoidable, there's always going to be dust. Cleaning products produce chemicals in the air."And another area that is really important is wood burning stoves. Everyone loves a wood burning stove - it's so lovely - but it really does produce a lot of indoor air pollution as well as outdoor." To understand how indoor air quality can be affected by everyday household tasks, I've borrowed an air monitor from Dr app tells me the air outside is good quality scoring 97 out of a possible 100. The higher the number the less measurable pollution is start with my indoor reading is about the same but it does not take long for things to go a piece of salmon, I light a fragranced candle to disguise the smell. A bit of vacuuming and spraying down the kitchen counter are also on the chores but surely the air quality starts to fall. Without burning the food it is down to 49 out of 100 - telling me the air quality is house just smells of cooking. I've never before thought of it as poor air quality. How low can you go? Curious to see what the monitor would show I decide to put two slices of bread into the toaster and crank it long whisps of smoke begin to fill the kitchen and the air quality is not long before the smoke alarm sounds and the smell of burned toast fills the entire indoor air monitor now reads zero, warning of severe pollution and telling me patients and members of sensitive groups may have to take emergency action. While poor air quality in the home is linked to household activities, which are usually short term, there is concern spikes in indoor air pollution could still be harmful."We do know that these spikes can induce changes in our bodies - so inflammation in the airways, in the cells of our airways and damage to the integrity of those airways to prevent other things getting in," warns Dr there is action you can take to reduce the levels of indoor pollution in your recommend always using an extractor fan when cooking and using the rear of the hob so that fumes go up the wall into the fan rather than towards the only dry, untreated wood at a high temperature will also help reduce emissions from wood the meantime, Dr Daniels is calling for more research into indoor air pollution to understand the problem we are all living with. You can follow BBC Hampshire & Isle of Wight on Facebook, X (Twitter), or Instagram.


BBC News
an hour ago
- BBC News
Dudley MP proud to lead first incontinence debate in Commons
A Labour MP has said she is proud to be leading a debate about incontinence that is the first of its kind in the House of Kumar, MP for Dudley, will chair the backbench business committee debate on Thursday, which will shine a light on the issues faced by those with pelvic health issues. Kumar said the issue "affected millions across the UK", however it remained "overlooked and under-discussed". She hoped the debate would help to bring incontinence "out of the shadows" and give it the "attention it deserves". The National Institute for Health and Care estimates that 34% of women had urinary Dudley MP, who is a physiotherapist, said she had worked closely with women to help them manage the challenges of pelvic floor had previously spoken about pelvic health during a Westminster debate on women's health and received a "wave of responses" from people who had similar experiences."These are not just medical conditions, they are deeply personal challenges that can significantly impact individuals' dignity, independence, and mental wellbeing," Kumar said. Mum-of-four Leanne Shakespeare, 51, said she experienced incontinence for nearly 30 years after she had a breach birth. "I have to wear towels when I leave the house, I'd love to go swimming again but I can't. "When I'm on holiday I couldn't take my shorts off or go in the water."Ms Shakespeare, who is from Kingswinford, said it had impacted her confidence and mental health. She added that it had taken her 10 years to tell anyone what she had experienced."It's a taboo and it isn't talked about enough, now I just have to get on with it and try not to let it stop me."Ms Shakespeare said the debate was a "great idea" and she planned to "follow it on TV". Polly Weston, co-chair of the Association for Continence Professionals, was pleased that the issue had "finally gained traction". "The government is talking about something that the nation is secretly trying to deal with", she said."People will quite happily talk about other medical problems, but the minute you talk about your bowels or bladder, it doesn't seem to be a conversation." Ms Weston said she had spoken to cancer patients who found it "more complex" to talk about their bladder and bowels than the treatment they had received. She added that the privacy towards incontinence was "culture and learnt behaviour" and called for health professionals to "ask patients more open questions" about the issue. Follow BBC Birmingham on BBC Sounds, Facebook, X and Instagram.


The Independent
an hour ago
- The Independent
How do the new antibody drugs for Alzheimer's disease work?
Two new drugs for Alzheimer's have been rejected for use on the NHS. They slow progression of the disease, but they can have serious side-effects. – What are the medicines? Donanemab and lecanemab are targeted antibody drugs that slow down the early stages of Alzheimer's. They represent a huge step forward in research because they target a known cause of the disease, rather than just treating the symptoms. Both drugs bind to amyloid, a protein which builds up in the brains of people living with Alzheimer's disease. By binding to amyloid, the drugs are designed to help clear the build-up and slow down cognitive decline. – How effective are they? Donanemab has been shown in clinical trials to slow the rate at which memory and thinking get worse by more than 20%. Evidence suggests that people get the most benefit if they are given the treatment earlier in the disease. Results also suggest the drug leads to a 40% slowing in the decline of everyday activities such as driving, enjoying hobbies and managing money. Lecanemab has also been shown to successfully remove protein build-up from the brains of people living with early Alzheimer's disease. For people taking lecanemab, this meant the decline in their thinking and memory skills was slowed down by 27%. It also slowed down the decline in quality of life by up to 56%. – How are the drugs given? Donanemab, developed by the pharmaceutical company Lilly, is given to patients via an intravenous drip once every four weeks. Lecanemab, developed by Eisai, is also given this way but fortnightly. – Are there any side-effects? Side-effects of the drugs can be serious and people undergo monitoring to check for them. In one clinical trial published in the Journal of the American Medical Association (JAMA) in 2023, 24% of people receiving donanemab had side-effects including brain swelling and infusion-related reactions. Four people died during the trial, with their deaths thought to be related to the drug's side-effects. Lecanemab resulted in infusion-related reactions in around 26% of people on the trial and followed up, while 14% suffered amyloid-related imaging abnormalities causing brain swelling. Others suffered minor bleeds picked up on scans. Around one in 10 people suffered headaches, according to updated results published in May 2024. Overall, four deaths during the follow-up period were thought to be due to treatment. – How much do the drugs cost? NHS England published a briefing paper last year suggesting the cost of bringing the drugs to the health service could be £500 million to £1 billion per year. Around 50%-60% of the total estimated cost relates to the drug price, with remaining cash spent on patient assessment, diagnosis and administering the treatment. – How many people in England might the drugs have worked for? NHS England estimated between 50,000 and 280,000 patients could be eligible for the new treatments if they were approved for the NHS. To get the drugs, patients need a baseline MRI scan and then either a PET-CT scan or lumbar puncture to confirm Alzheimer's. It is possible that blood tests will be available in the future to diagnose the disease, so NHS England did warn there should be caution about driving a 'massive expansion' in other diagnostics which could become redundant in the longer term. -What do scientists think? Scientists and doctors have been divided on whether the drugs represent a real clinical benefit that is noticeable in patients day-to-day. Some argue the drugs represent a huge advance and people should be given the chance to try them. But others say the benefits are too small. Jennifer Keen, associate director of evidence, policy and influencing at the Alzheimer's Society, has said: 'we remain at an important and exciting moment', adding: 'There are currently 182 active clinical trials for Alzheimer's disease… We are on the cusp of major scientific breakthroughs beginning to improve the outlook for those with the disease.' Professor Rob Howard, from University College London, said: 'Nobody should be surprised that Nice have confirmed their earlier view that the new Alzheimer's disease treatments would not be cost-effective if used within the NHS. 'Well-conducted clinical trials demonstrated that the actual size of benefits experienced by patients were too small to be noticeable, treatment carries risks of side-effects, and the annual cost of the drugs and safety monitoring required would have been close to the cost of a nurse's salary for each treated patient. We need better treatments that can make an appreciable difference to the lives of people with dementia and these can only come from further research and study.'